专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20170065690A1 Tscm CELLS AND METHODS FOR USE 审中-公开
标题翻译： Tscm细胞和使用方法
公开(公告)号：US20170065690A1
公开(公告)日：2017-03-09
申请号：US15120236
申请日：2015-02-20
申请人： Argos Therapeutics, Inc.
发明人： Mark DeBenedette , Charles Nicolette , Joseph Horvatinovich
IPC分类号： A61K39/00 , G01N33/50
CPC分类号： A61K39/0011 , A61K35/15 , A61K35/17 , A61K2039/5158 , C12N5/0638 , C12N5/0639 , C12N2501/52 , C12N2506/11 , G01N33/5005 , G01N33/5091 , G01N2800/52
摘要： The present invention relates to TSCM cells and uses thereof. TSCM cells can be used help identify and treat patients who are likely to experience particular treatment outcomes. In other embodiments TSCM cells are generated in vitro and used for adoptive transfer therapy.
摘要翻译：本发明涉及TSCM细胞及其应用。可以使用TSCM细胞来帮助识别和治疗可能经历特定治疗结果的患者。在其他实施方案中，TSCM细胞在体外产生并用于过继转移治疗。

2. 发明申请

US20160008440A1 Use of CD83 in Combination Therapies 审中-公开
标题翻译：在组合疗法中使用CD83
公开(公告)号：US20160008440A1
公开(公告)日：2016-01-14
申请号：US14872356
申请日：2015-10-01
申请人： Argos Therapeutics, Inc.
发明人： Charles Nicolette , Stephen Brand , Zhen Zhong , Hao Wang , Jacqueline Arp , Siobhan Ramcharran , Miren Lorea Baroja
IPC分类号： A61K38/47 , A61K39/395 , A61K31/436 , A61K31/341 , A61K38/45 , A61K38/13
CPC分类号： A61K38/1774 , A61K9/0019 , A61K9/0053 , A61K31/341 , A61K31/365 , A61K31/4353 , A61K31/436 , A61K31/5377 , A61K35/12 , A61K35/761 , A61K38/13 , A61K38/1709 , A61K38/30 , A61K38/45 , A61K38/47 , A61K39/3955 , A61K45/06 , A61K48/00 , C07K14/70503 , C07K16/289 , C12N2750/14143 , C12Y204/99 , C12Y302/02006 , A61K2300/00
摘要： The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.
摘要翻译：本发明涉及抑制和/或预防包括使用CD83的不期望的免疫应答的改进方法。在一些实施方案中，CD83与至少一种其它免疫抑制化合物共同施用于受试者。还提供了用于产生耐受性树突状细胞和调节性T细胞的方法。这些细胞可以在体外用于产生用于治疗目的的另外的细胞，或者它们可以在体内用于抑制和/或预防不期望的免疫应答。本发明的方法可用于预防或降低自身免疫疾病的严重性，并且还可用于诱导对至少一种治疗组合物如治疗性蛋白质或移植组织的耐受性。

3. 发明申请

US20160324926A1 Use of CD83 in Combination Therapies 审中-公开
公开(公告)号：US20160324926A1
公开(公告)日：2016-11-10
申请号：US15155287
申请日：2016-05-16
申请人： Argos Therapeutics, Inc.
发明人： Charles Nicolette , Stephen Brand , Zhen Zhong , Hao Wang , Jacqueline Arp , Siobhan Ramcharran , Miren Lorea Baroja
IPC分类号： A61K38/17 , C07K16/28 , A61K9/00 , A61K31/365 , A61K31/436 , A61K38/13 , A61K39/395
CPC分类号： A61K38/1774 , A61K9/0019 , A61K9/0053 , A61K31/341 , A61K31/365 , A61K31/4353 , A61K31/436 , A61K31/5377 , A61K35/12 , A61K35/761 , A61K38/13 , A61K38/1709 , A61K38/30 , A61K38/45 , A61K38/47 , A61K39/3955 , A61K45/06 , A61K48/00 , C07K14/70503 , C07K16/289 , C12N2750/14143 , C12Y204/99 , C12Y302/02006 , A61K2300/00
摘要： The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.

4. 发明申请

US20150252083A1 Strain-Independent Amplification of Pathogens and Vaccines Thereto 有权
标题翻译：病原菌和疫苗的应变无关扩增
公开(公告)号：US20150252083A1
公开(公告)日：2015-09-10
申请号：US14659487
申请日：2015-03-16
申请人： Argos Therapeutics, Inc.
发明人： Charles Nicolette , Irina Tcherepanova , Jason Harris , Donald Healey
IPC分类号： C07K14/005 , C12N7/00 , A61K39/21
CPC分类号： C07K14/005 , A61K39/21 , A61K2039/5154 , A61K2039/5156 , C12N7/00 , C12N2740/16041 , C12N2740/16234 , C12N2740/16334 , C12Q1/703
摘要： This in invention relates to methods for the nucleic acid amplification of multiple variants (strains) of any pathogen present in a sample, and preferably in a sample from a pathogen infected individual. In preferred embodiments, the pathogen is a retrovirus, such as HIV. The amplified pathogen nucleic acid can be used to identify the pathogen variants present in a sample, to quantitate the pathogen present in a sample, and as a nucleic acid vaccine, or in the preparation of antigen presenting cell vaccines. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can be used to transfect/load antigen presenting cells. The loaded antigen presenting cells can then be used as a vaccine for the treatment of pathogen infection. In another embodiment, nucleic acids produced by the methods of the invention can be used directly as nucleic acid vaccines without prior loading into antigen presenting cells.
摘要翻译：本发明涉及用于核酸扩增样品中存在的任何病原体的多种变体（菌株）的方法，优选来自病原体感染个体的样品。在优选的实施方案中，病原体是逆转录病毒，例如HIV。扩增的病原体核酸可用于鉴定样品中存在的病原体变体，以定量样品中存在的病原体，以及作为核酸疫苗，或用于制备抗原呈递细胞疫苗。通过本发明的方法产生的核酸或由其编码的蛋白质可用于转染/负载抗原呈递细胞。然后将负载的抗原呈递细胞用作用于治疗病原体感染的疫苗。在另一个实施方案中，通过本发明的方法产生的核酸可以直接用作核酸疫苗而不预先加载到抗原呈递细胞中。

5. 发明授权

US09879053B2 Strain-independent amplification of pathogens and vaccines thereto 有权
公开(公告)号：US09879053B2
公开(公告)日：2018-01-30
申请号：US14659487
申请日：2015-03-16
申请人： Argos Therapeutics, Inc.
发明人： Charles Nicolette , Irina Tcherepanova , Jason Harris , Donald Healey
IPC分类号： A61K45/06 , C07K14/005 , C12Q1/70 , A61K39/21 , C12N7/00 , A61K39/00
CPC分类号： C07K14/005 , A61K39/21 , A61K2039/5154 , A61K2039/5156 , C12N7/00 , C12N2740/16041 , C12N2740/16234 , C12N2740/16334 , C12Q1/703
摘要： This in invention relates to methods for the nucleic acid amplification of multiple variants (strains) of any pathogen present in a sample, and preferably in a sample from a pathogen infected individual. In preferred embodiments, the pathogen is a retrovirus, such as HIV. The amplified pathogen nucleic acid can be used to identify the pathogen variants present in a sample, to quantitate the pathogen present in a sample, and as a nucleic acid vaccine, or in the preparation of antigen presenting cell vaccines. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can be used to transfect/load antigen presenting cells. The loaded antigen presenting cells can then be used as a vaccine for the treatment of pathogen infection. In another embodiment, nucleic acids produced by the methods of the invention can be used directly as nucleic acid vaccines without prior loading into antigen presenting cells.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式